+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Wound Biologics Market by Product Type, Application, End User, Distribution Channel - Global Forecast to 2030- Product Image
Wound Biologics Market by Product Type, Application, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Wound Biologics Market by Product Type, Application, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4989966
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Wound Biologics Market grew from USD 5.43 billion in 2024 to USD 5.99 billion in 2025. It is expected to continue growing at a CAGR of 10.16%, reaching USD 9.71 billion by 2030.

Setting the Stage for Wound Biologics Innovation

Wound biologics represent a transformative frontier in tissue regeneration and healing, driven by breakthroughs in molecular biology, advanced biomaterials, and precision medicine. This executive summary distills the critical drivers reshaping the industry, offering decision-makers a concise yet thorough orientation. As the complexity of chronic wounds and the demand for accelerated healing rises, the market is witnessing an unprecedented convergence of biologically active molecules, engineered scaffolds, and personalized therapies. The advancing regulatory landscape, combined with shifting reimbursement paradigms, underscores the necessity for stakeholders to anticipate change and adapt strategically.

Through a structured analysis of emerging trends, tariff implications, market segmentation, regional dynamics, and competitive positioning, this overview sets the foundation for informed planning and investment. It highlights the need for a holistic approach that integrates scientific innovation with operational resilience and market intelligence. Whether you are a developer charting your product roadmap or an investor evaluating growth potential, the insights that follow will illuminate the pathways to sustainable value creation in the wound biologics arena.

Evolving Dynamics Shaping the Future of Wound Care

Over the past decade, the wound biologics landscape has undergone a profound transformation, driven by advancements in cellular therapies, signaling proteins, and next-generation biomaterials. Regenerative approaches once confined to niche applications are now moving toward mainstream acceptance, fueled by compelling clinical data and enhanced manufacturing capabilities. Concurrently, digital technologies have enabled real-time wound monitoring, allowing for adaptive interventions that optimize healing trajectories.

In parallel, the regulatory environment has evolved to accommodate accelerated pathways for breakthrough therapies, encouraging developers to invest in robust clinical designs and post-market surveillance frameworks. Reimbursement models are increasingly outcome-based, aligning cost structures with healing efficacy and long-term patient benefits. This paradigm shift compels manufacturers and clinicians to focus on demonstrable value rather than incremental improvements. Furthermore, heightened patient awareness and advocacy have spurred demand for personalized treatment options, reinforcing the imperative for targeted biologic formulations and precision delivery systems.

Assessing the Impact of 2025 US Tariffs on Supply Chain Resilience

In anticipation of United States tariffs slated for 2025, market participants must navigate a complex matrix of import duties and trade compliance measures that threaten to alter cost structures across the supply chain. Components such as recombinant proteins, collagen sources, and specialized dressings may face elevated duties, compelling manufacturers to reassess sourcing strategies and negotiate new supplier agreements. This landscape fosters an environment where vertical integration and local manufacturing emerge as viable pathways to mitigate tariff exposure and maintain price competitiveness.

Moreover, distributors and end users are poised to recalibrate inventory management and procurement cycles, balancing the risk of cost increases against the need for uninterrupted access to critical biologic therapies. In response, strategic alliances and joint ventures offer a mechanism to share risk and capitalize on regional incentives aimed at bolstering domestic production. Ultimately, those organizations that proactively model tariff scenarios and implement adaptive supply chain frameworks will secure a distinct advantage in preserving both margin integrity and market reach.

Insights from Multidimensional Market Segmentation

The wound biologics market can be dissected through multiple analytical lenses, beginning with product types encompassing collagen matrices, growth factor formulations, platelet-derived therapies, and skin-substitute technologies. Within the collagen category, animal-derived variations such as bovine, equine, and porcine sources each present unique biocompatibility profiles and supply considerations. Growth factors-ranging from epidermal and fibroblast factors to platelet-derived and vascular endothelial components-offer divergent modes of action in tissue repair. Platelet derivatives, whether presented as fibrin constructs or plasma concentrates, deliver autologous regenerative cues. Skin substitutes span biological dermal layers, composite scaffolds, and fully synthetic constructs engineered for enhanced mechanical resilience.

Application-specific segmentation reveals focus areas such as acute wounds that demand rapid closure, burn treatments stratified by second-degree and third-degree classifications, chronic wound care addressing diabetic foot, pressure, and venous leg ulcers, and surgical wound management tailored to perioperative healing. End-user environments vary from ambulatory surgical centers and home-care settings to traditional hospital systems and dedicated wound-care clinics, each exhibiting distinct procurement protocols and volume requirements. Distribution channels further delineate market dynamics, with direct sales models, hospital pharmacy networks, digital pharmacy platforms, and retail pharmacy outlets each contributing to accessibility and patient outreach.

Unveiling Regional Variations and Market Entry Imperatives

Regional performance in the wound biologics arena underscores divergent growth trajectories and competitive landscapes across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In North and South America, established reimbursement frameworks and robust research infrastructure have fostered rapid adoption of innovative therapies alongside legacy biologic dressings. The Europe, Middle East & Africa region is characterized by heterogeneous regulatory regimes and varying healthcare funding levels, prompting manufacturers to employ differentiated market access strategies calibrated to national formularies and tender systems. Meanwhile, Asia-Pacific exemplifies dynamic expansion driven by rising incidence of chronic wounds, increased healthcare spending, and supportive government initiatives aimed at localizing production and enhancing clinical trial capacity.

These regional nuances demand tailored go-to-market approaches that account for reimbursement variability, clinical practice patterns, and patient demographics. Cross-border partnerships and licensing agreements continue to be pivotal in bridging technical expertise with distribution capabilities. As market saturation intensifies in mature geographies, emerging markets present fertile ground for entry via strategic collaborations and capacity-building investments in manufacturing and training.

Profiling the Innovators and Market Leaders

Within this competitive landscape, a cadre of established leaders and emerging contenders are competing on the basis of product innovation, strategic alliances, and global footprint. Legacy firms leverage deep regulatory experience and broad portfolios spanning collagen-based scaffolds, advanced growth factors, and composite substitutes. At the same time, specialized biotechnology companies focus on next-generation cell therapies, novel polyprotein constructs, and customizable delivery matrices. Collaborative ventures between bioscience startups and contract development organizations accelerate the translation of early-stage research into scalable manufacturing processes.

Key market participants differentiate through vertically integrated operations, proprietary intellectual property, and expansive clinical networks that facilitate robust evidence generation. Partnerships with academic institutions and hospital systems underpin many late-stage trials, enhancing the evidentiary basis for outcome-based reimbursement negotiations. Furthermore, M&A activity continues to reshape competitive dynamics, enabling leading players to augment their technology stacks and broaden geographic reach in a single transaction.

Strategic Actions to Secure Long-Term Competitive Advantage

As the wound biologics sector moves into its next phase of growth, strategic imperatives for industry leaders hinge on several fronts. First, investment in modular manufacturing platforms-capable of handling diverse biologic modalities-will streamline scale-up and reduce time to market. Second, forging alliances with digital health providers to integrate real-time wound analytics can substantiate value claims and unlock outcome-based reimbursement pathways. Third, developing a diversified supplier base and exploring contract manufacturing partnerships can buffer the impact of geopolitical uncertainties and tariff fluctuations.

Additionally, companies should prioritize the generation of real-world evidence through post-market registries and data partnerships, thereby reinforcing the clinical and economic benefits of their offerings. Engaging with payors and policy makers early in product development will align trial endpoints with coverage criteria, expediting market access. Lastly, a customer-centric approach that spans clinician education, patient support programs, and telemedicine initiatives will differentiate market leaders in an increasingly crowded field.

Underlying Research Framework and Data Integrity

This analysis draws upon a rigorous research methodology designed to ensure depth, validity, and actionable insight. Primary research included structured interviews with key opinion leaders in wound care, product development executives, and procurement specialists across major healthcare institutions. Secondary sources consisted of peer-reviewed literature, regulatory filings, policy frameworks, and industry white papers. Comprehensive data triangulation was achieved by cross-referencing interview findings with published market intelligence and historical trend analyses.

To enhance reliability, all qualitative inputs underwent stakeholder validation workshops, while quantitative assessments were subjected to consistency checks against supply-side production capacities and distribution channel performance metrics. Ethical considerations and data privacy standards were meticulously maintained throughout the process. The resulting framework offers a transparent, repeatable approach for evaluating emerging opportunities and risks within the wound biologics sector.

Navigating Opportunities and Challenges Ahead

The wound biologics market stands at a critical inflection point where scientific innovation, regulatory evolution, and shifting reimbursement models converge. Stakeholders who embrace a proactive stance-characterized by supply chain resilience, evidence generation, and strategic partnerships-will thrive in this complex environment. Contrastingly, organizations reliant on traditional product portfolios and static commercial approaches may struggle to adapt to rapidly changing payor expectations and patient-centric care models.

By synthesizing insights across market dynamics, segmentation intricacies, regional disparities, and competitive positioning, this executive summary has charted the contours of opportunity and disruption. It underscores the enduring role of biologic therapies in meeting unmet clinical needs while highlighting the imperative for agility and collaboration. As the sector progresses, continuous monitoring of policy shifts, technological breakthroughs, and emerging clinical data will be essential to sustaining growth and delivering superior patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Collagen
      • Bovine Collagen
      • Equine Collagen
      • Porcine Collagen
    • Growth Factors
      • Epidermal Growth Factor
      • Fibroblast Growth Factor
      • Platelet Derived Growth Factor
      • Vascular Endothelial Growth Factor
    • Platelet Derivatives
      • Platelet Rich Fibrin
      • Platelet Rich Plasma
    • Skin Substitutes
      • Biological Dermal
      • Composite Dermal
      • Synthetic Dermal
  • Application
    • Acute Wounds
    • Burns
      • Second Degree Burns
      • Third Degree Burns
    • Chronic Wounds
      • Diabetic Foot Ulcer
      • Pressure Ulcer
      • Venous Leg Ulcer
    • Surgical Wounds
  • End User
    • Ambulatory Surgical Centers
    • Home Care
    • Hospitals
    • Wound Care Centers
  • Distribution Channel
    • Direct Sales
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • 3M Company
  • Organogenesis Inc.
  • Smith & Nephew plc
  • Mölnlycke Health Care AB
  • Integra LifeSciences Holdings Corporation
  • MiMedx Group, Inc.
  • Celularity, Inc.
  • Avita Medical Ltd.
  • Alliqua BioMedical, Inc.
  • CollPlant Biotechnologies Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Wound Biologics Market, by Product Type
8.1. Introduction
8.2. Collagen
8.2.1. Bovine Collagen
8.2.2. Equine Collagen
8.2.3. Porcine Collagen
8.3. Growth Factors
8.3.1. Epidermal Growth Factor
8.3.2. Fibroblast Growth Factor
8.3.3. Platelet Derived Growth Factor
8.3.4. Vascular Endothelial Growth Factor
8.4. Platelet Derivatives
8.4.1. Platelet Rich Fibrin
8.4.2. Platelet Rich Plasma
8.5. Skin Substitutes
8.5.1. Biological Dermal
8.5.2. Composite Dermal
8.5.3. Synthetic Dermal
9. Wound Biologics Market, by Application
9.1. Introduction
9.2. Acute Wounds
9.3. Burns
9.3.1. Second Degree Burns
9.3.2. Third Degree Burns
9.4. Chronic Wounds
9.4.1. Diabetic Foot Ulcer
9.4.2. Pressure Ulcer
9.4.3. Venous Leg Ulcer
9.5. Surgical Wounds
10. Wound Biologics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Home Care
10.4. Hospitals
10.5. Wound Care Centers
11. Wound Biologics Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Hospital Pharmacies
11.4. Online Pharmacies
11.5. Retail Pharmacies
12. Americas Wound Biologics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Wound Biologics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Wound Biologics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. 3M Company
15.3.2. Organogenesis Inc.
15.3.3. Smith & Nephew plc
15.3.4. Mölnlycke Health Care AB
15.3.5. Integra LifeSciences Holdings Corporation
15.3.6. MiMedx Group, Inc.
15.3.7. Celularity, Inc.
15.3.8. Avita Medical Ltd.
15.3.9. Alliqua BioMedical, Inc.
15.3.10. CollPlant Biotechnologies Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. WOUND BIOLOGICS MARKET MULTI-CURRENCY
FIGURE 2. WOUND BIOLOGICS MARKET MULTI-LANGUAGE
FIGURE 3. WOUND BIOLOGICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. WOUND BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. WOUND BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. WOUND BIOLOGICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. CANADA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 73. CANADA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 74. CANADA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 75. CANADA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 76. CANADA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 78. CANADA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 79. CANADA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MEXICO WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 83. MEXICO WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 85. MEXICO WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 86. MEXICO WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. MEXICO WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. GERMANY WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 134. GERMANY WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 136. GERMANY WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 137. GERMANY WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. GERMANY WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. GERMANY WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. FRANCE WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. FRANCE WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 144. FRANCE WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 147. FRANCE WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ITALY WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 164. ITALY WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 165. ITALY WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 166. ITALY WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 167. ITALY WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. ITALY WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 169. ITALY WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 170. ITALY WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ITALY WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SPAIN WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. SPAIN WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 174. SPAIN WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 176. SPAIN WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 177. SPAIN WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. SPAIN WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 179. SPAIN WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SPAIN WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. DENMARK WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. DENMARK WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 214. DENMARK WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 216. DENMARK WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 217. DENMARK WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. DENMARK WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 219. DENMARK WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 220. DENMARK WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. DENMARK WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. QATAR WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. QATAR WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 234. QATAR WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 235. QATAR WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 236. QATAR WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 237. QATAR WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. QATAR WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 239. QATAR WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 240. QATAR WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. QATAR WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. FINLAND WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. FINLAND WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 244. FINLAND WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 246. FINLAND WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 247. FINLAND WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. FINLAND WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 249. FINLAND WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. FINLAND WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. EGYPT WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 273. EGYPT WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 274. EGYPT WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 276. EGYPT WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 277. EGYPT WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. EGYPT WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 279. EGYPT WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 280. EGYPT WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. EGYPT WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. TURKEY WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. TURKEY WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 284. TURKEY WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 286. TURKEY WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 287. TURKEY WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. TURKEY WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 289. TURKEY WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 290. TURKEY WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. TURKEY WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. NORWAY WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. NORWAY WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 304. NORWAY WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 306. NORWAY WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 307. NORWAY WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. NORWAY WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 309. NORWAY WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. NORWAY WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. POLAND WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 313. POLAND WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 314. POLAND WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 315. POLAND WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 316. POLAND WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 317. POLAND WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 318. POLAND WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 319. POLAND WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 320. POLAND WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. POLAND WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. SWITZERLAND WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 336. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 339. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 340. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 342. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 343. CHINA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 344. CHINA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 345. CHINA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 346. CHINA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 347. CHINA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2030 (USD MILLION)
TABLE 348. CHINA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 349. CHINA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2030 (USD MILLION)
TABLE 350. CHINA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
TABLE 351. CHINA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 352. CHINA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 353. INDIA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 354. INDIA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2030 (USD MILLION)
TABLE 355. INDIA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2030 (USD MILLION)
TABLE 356. INDIA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2030 (USD MILLION)
TABLE 35

Companies Mentioned

The companies profiled in this Wound Biologics market report include:
  • 3M Company
  • Organogenesis Inc.
  • Smith & Nephew plc
  • Mölnlycke Health Care AB
  • Integra LifeSciences Holdings Corporation
  • MiMedx Group, Inc.
  • Celularity, Inc.
  • Avita Medical Ltd.
  • Alliqua BioMedical, Inc.
  • CollPlant Biotechnologies Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.99 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.71 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Wound Care Biologics Market Report by Product, Wound Type, Application, End-User, and Region 2025-2033 - Product Image

Wound Care Biologics Market Report by Product, Wound Type, Application, End-User, and Region 2025-2033

  • Report
  • 140 Pages
  • Global
From
Wound Care Biologics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Wound Care Biologics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 132 Pages
  • Global
From
Wound Care Biologics - Global Strategic Business Report - Product Image

Wound Care Biologics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Wound Care Biologics Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Wound Care Biologics Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 157 Pages
  • Global
From
Wound Care Biologics Market Report 2025 - Product Image

Wound Care Biologics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.